Anti-CD19 CAR-T cell therapy in relapsed/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expression

Xiaomin Zhang(Shenzhen University Health Science Center), Yu Li(Shenzhen University Health Science Center)
Frontiers in Immunology
July 21, 2025
10.3389/fimmu.2025.1617589
Cited by 4

Related Papers

HDAC6 Is Required for Epidermal Growth Factor-induced β-Catenin Nuclear Localization
|Journal of Biological Chemistry|2008|174
Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
|Cancer Research|2023|81
BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
|Scientific Reports|2021|44